Dutch-based TargED raises €21.5 million Series A extension to advance targeted treatments for thrombotic diseases
Dutch clinical-stage BioTech company TargED Biopharmaceuticals has announced the closing of a €21.5 million Series A extension financing to accelerate the clinical development of its targeted thrombolytic, TGD001.
The round was led by BioGeneration Ventures (BGV), with participation from existing investors, including Andera Partners, Fund+, Hadean Ventures, Inkef Capital, Sunstone Life Science Ventures, and Curie Capital. With this extension, TargED’s total Series A funding now exceeds €60 million.
“The momentum behind TGD001 continues to build — from compelling preclinical data to encouraging first clinical use — and this financing enables us to move decisively into the next stage of development. We believe TGD001 has the potential to fundamentally reshape the treatment of thrombosis, offering a novel approach to universally dissolving clots across multiple life-threatening indications,” said Kristof Vercruysse, CEO and co-founder of TargED Biopharmaceuticals.
This spin-off of the University Medical Centre Utrecht was founded in 2020 by Coen Maas, Steven de Maat, Marc van Moorsel, and Kristof Vercruysse. TargED stands for Targeted Enzyme Delivery, and the company develops targeted treatments for thrombotic diseases.
Its lead compound is TGD001, a targeted thrombolytic designed to treat a wide range of thrombotic events. As an antibody-enzyme fusion protein, TGD001 binds to von Willebrand factor (VWF) and promotes site-specific clot breakdown through the action of the enzyme urokinase, TargED explained.
Further explaining TGD001’s edge over other currently-approved therapies, the Dutch company mentioned that the thrombolytic leverages the ubiquitous presence of VWF in all clots, enabling broad clot lysis by degrading both VWF and fibrin
Earlier this month, the company reported positive Phase 1 first-in-human results for TGD001, citing a favourable safety profile and potent thrombolytic activity. It will be further developed for the treatment of acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).
With this new financing, TargED aims to initiate two Phase 1/2 clinical proof-of-concept studies across Europe and the U.S., with first data expected in 2026. Earlier this year, in June, the company was awarded a blended finance grant from the European Innovation Council (EIC) under the EIC Accelerator programme. The funding included a €2.5 million grant and up to €10 million in equity investment.
The post Dutch-based TargED raises €21.5 million Series A extension to advance targeted treatments for thrombotic diseases appeared first on EU-Startups.
